<DOC>
	<DOC>NCT01906749</DOC>
	<brief_summary>Multicenter, double blind, randomized trial to assess the effect of low-dose colchicine (0.5mg/day) on overall mortality, new coronary syndromes, and ischemic stroke at 2 years after an acute coronary syndrome. The study hypothesis is that colchicine may reduce the specified combined endpoint from 16% to 7-8% at a 2-years follow-up.</brief_summary>
	<brief_title>Colchicine for Acute Coronary Syndromes</brief_title>
	<detailed_description>Multicenter, double-blind randomized trial to evaluate the efficacy of low dose colchicine (0.5mg once daily for 2 years) to reduce the incidence of subsequent overall mortality, new acute coronary syndromes, and ischemic stroke in patients admitted for an acute coronary syndrome.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>&gt;18years Acute coronary syndrome (unstable angina or acute myocardial infarction) Life expectancy&gt; 2 years Absence of contraindications to colchicine Colchicine treatment for any cause Severe liver disease Renal insufficiency with creatinine&gt;150mmol/l or creatinine clearance&lt;30ml/min/1.73m2 Known cancer Chronic inflammatory bowel disease treatment with cyclosporine allergy or hypersensitivity to colchicine pregnancy or lactating woman or woman with childbearing potential without valid contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Colchicine</keyword>
</DOC>